Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CICERO trial of intracoronary versus intravenous abciximab during primary PCI for STEMI
NL-OMON32667Phase 4Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of abciximab in myocardial infarction (MI) (2 arms), sponsored by University Medical Center Groningen. Started Sep 2008; status: recruiting.
02
Drugs
abciximab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON32667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32667.